Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)

Active
Yes
Status
Posted
Published Date
March 14th, 2024
Close Date
November 13th, 2024
Award Ceiling
$275,000.00
Opportunity No.
RFA-DA-25-005

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)". This grant aims to support research focused on identifying and characterizing neuroimmune networks, communication pathways, and targets related to HIV and substance use. The grant also seeks to fund research on the discovery of novel modulatory probes/tools that can enhance our understanding of the regulatory mechanisms underlying the comorbidity of HIV and substance use disorder. The grant has a funding ceiling of $275,000 and does not require cost sharing or matching. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for applications is November 13, 2024. For more information and to apply, visit the following link: Research on the Neuro-Immune Axis Grant. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

The purpose of this notice of funding opportunity (NOFO) is to support research towards identifying and characterizing neuroimmune networks, communication pathways, and targets that reside within neuroimmune axes, in the context of HIV and substance use. This NOFO will also support research on the discovery of novel modulatory probes/tools that can advance our knowledge of the regulatory mechanisms by which neuroimmune interactions contribute to HIV and substance use disorder comorbidity.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)". This grant aims to support research focused on identifying and characterizing neuroimmune networks, communication pathways, and targets related to HIV and substance use. The grant also seeks to fund research on the discovery of novel modulatory probes/tools that can enhance our understanding of the regulatory mechanisms underlying neuroimmune interactions in the context of HIV and substance use disorder comorbidity. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is November 13, 2024. For more information and to apply, visit the following link: [Research on the Neuro-Immune Axis Grant](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-004.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)". This grant aims to support research that investigates the role of inflammasomes in the neuropathology caused by drug exposure and HIV infection. By understanding the involvement of inflammasomes in virus and drug-induced immune activation, this research may help identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations. Additionally, it may lead to the development of novel therapies to target inflammasome activation or suppression for the treatment of neuroinflammation and immune dysregulation. The grant has a funding ceiling of $275,000 and does not require cost sharing or matching. The deadline for applications is March 13, 2025. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-013.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-013.html).
Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Targeting Inflammasomes in HIV and Substance Use" under the category of Health. This grant aims to support research that investigates the role of inflammasomes in the neuropathology caused by drug exposure and HIV infection. The objective is to understand how inflammasomes contribute to immune activation and identify molecular markers and CNS immune cells associated with HIV-1 infection or disease progression among substance abuse populations. The research will also focus on identifying novel therapies to target inflammasome activation or suppression for the treatment of neuroinflammation and immune dysregulation. The grant does not require cost sharing or matching requirements and has a maximum award ceiling of $500,000. The eligibility for this grant is open to various entities, including Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for applications is March 13, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-012.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-012.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed)". This grant aims to support research that addresses the interplay between autophagy orchestrated cell death and HIV pathogenesis, with a focus on the central nervous system (CNS) cellular immune responses influenced by acute and chronic drug use. The grant does not require cost sharing or matching requirements and falls under the category of funding activity for health. The maximum award ceiling for this grant is $275,000. Other eligible applicants, in addition to the NIH, include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The grant opportunity will close on November 14, 2024, and the archive date is set for December 20, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-010.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-010.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.